Shares of Amarin Corp. /zigman2/quotes/201885540/composite AMRN -1.56% rose about 20% on Nasdaq-leading volume after a Food and Drug Administration committee released documents saying that the company' prescription fish-oil pill Vascepa has a "favorable benefit/risk profile" for a cardiovascular indication. The FDA's Endocrinologic and Metabolic Drugs Advisory Committee is expected to meet Thursday to discuss the company's application for the new indication. Amarin's net product revenue rose 104% to $112.3 million in the third quarter of 2019, up from $55 million in the like-period a year ago. That increase was driven by higher sales of Vascepa, Amarin's only FDA-approved drug. The company also said last week that it plans to double the size of its sales force to 800 from 400 in preparation of a potential FDA approval for the new indication. The FDA action date for approval is Dec. 28. Shares of Amarin are up 41.51% year-to-date, while the S&P 500 /zigman2/quotes/210599714/realtime SPX +0.45% has risen 23%.